InPheno has been assembling a precious collection of essential tools to meet the complexity of discovery and development of antiretroviral agents. InPheno's HIV platform was designed to help our customers address the issues raised by the FDA in its "points-to-consider" documents on anti-HIV drug development.
Our comprehensive HIV platform allows for the evaluation of antiviral activities in established cell lines and / or in human primary cells using either recombinant viruses or well characterized clinical isolates. All our HIV assays recapitulate the entire virus life cycle and are replicative, be they performed using primary cells or established cell lines.
Our platform enables:
- High throughput screening for new antiviral principles, be they synthetic compounds or natural products
- Activity profiling of lead candidate inhibitors
- Identification of the mode of action of lead compounds
- Drug combination studies
- In vitro selection of resistant viruses and their characterization
- Functional characterization of neutralizing antibodies for vaccine studies
- Phenotypic resistance testing starting from primary clinical specimens
Available assets for your studies include:
- Extended bank of characterized, fully infectious recombinant HIV-1 isolates and variants
- Clonal HIV-1 variants with individual or complex mutations in gag, protease, reverse transcriptase, integrase, or env genes
- Characterized (multi-)drug resistant HIV-1 mutants
- Service for engineering HIV-1 variants according to your needs
- HIV-1 clinical isolates of all common subtypes
- HIV-2 clinical isolates
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
